Type 2 diabetes: combining H. pylori treatment with metformin appears to improve HbA1c

Could treating Helicobacter pylori improve diabetes control? A randomized trial in 120 adults with type 2 diabetes and infection with this bacterium reports a greater improvement in HbA1c with treatment combined with metformin. But the analysis relies on aggregate data, without confirmation that the bacterium was eliminated. It therefore does not demonstrate that eradication explains the observed benefit.

Illustration of the stomach and HbA1c monitoring in a study on Helicobacter pylori and type 2 diabetes.
NutritionEditorial illustration, not study data.

Three treatments compared over six months

This single-center, open-label trial randomly assigned participants to three groups of 40 people: treatment aimed at eradicating H. pylori, metformin alone, or a combination of both. The primary outcome was the change in glycated hemoglobin, or HbA1c, from baseline to six months.

The supplied PubMed abstract was the only source consulted. It does not detail the eradication regimen or the doses administered. It therefore does not allow a precise comparison of these treatments with usual care.

A substantial difference in HbA1c

In the main model, combined treatment was associated with an additional HbA1c reduction of 1.76 percentage points compared with eradication treatment alone, and 1.77 percentage points compared with metformin alone. The 95% confidence intervals were 1.43 to 2.09 and 1.41 to 2.13 percentage points, respectively.

These figures describe differences in reductions between groups, not final HbA1c values or a guaranteed response for every patient. The incidence of complications did not differ significantly between groups. This finding demonstrates neither equivalence between treatments nor a benefit for diabetes complications.

The effect of eradication remains unproven

The main limitation concerns the data available for analysis: the researchers had only archived means, standard deviations, and sample sizes for each group at each measurement time point, without individual longitudinal data. Their model therefore relied on assumptions about the correlation between successive measurements.

Crucially, no confirmation of H. pylori elimination after treatment was available. The authors therefore present their findings as associations with treatment assignment, not as evidence of an effect linked to successful eradication.

This trial provides a signal that warrants further investigation in people with diabetes who are infected. On its own, it does not justify treating H. pylori solely to lower HbA1c, or changing diabetes medication.

Limitations to keep in mind

Single-center, open-label trial, analysis of aggregate data, and no confirmation of eradication. Only the PubMed abstract was consulted, not the full text. Funding, conflicts of interest, and details of adverse effects could not be verified.

What we can take away

The combination studied appears to improve HbA1c more at six months, but the role of H. pylori eradication and any lasting clinical benefit remain uncertain.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.